Parabilis Medicines
About Parabilis Medicines
Parabilis Medicines is a biopharmaceutical company focused on developing ultra-tunable peptide therapeutics to address cancer and other diseases with high unmet need. The company emphasizes a research-driven approach, aiming to deploy a novel modality to achieve transformative patient outcomes. Its communications highlight a strategic focus on innovation and science-driven programs, including clinical exploration of its medicines. While the exact geographic headquarters aren’t stated in the available content, Parabilis presents itself as a dedicated biotech entity advancing next-generation peptide medicines.
Recent News
Parabilis Heads Biotech Fundraising Frenzy With $305M to Advance Cancer Drug
Parabilis’ Path From POC to New Indications and Challenging Targets
The Week’s 10 Biggest Funding Rounds: XAI Leads As 2026 Is Off To A Brisk Start
Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive Β-Catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors
The Biggest Biotech Funding Rounds in January 2026
Parabilis Gets $305M to Tackle ‘Undruggable’ Proteins
